Analyst Research Report Snapshot

Title:

MOSL: PVR (Buy) - Revenue declines, margins lower than estimate

Price:

$81.00

Provider:

Motilal Oswal Securities Ltd.

Date:

04 Feb 2014

Pages:

10

Type:

AcrobatPDF

Companies referenced:

PVRL.NS

Available for Immediate Download
Summary:

PVR (PVRL IN, Mkt Cap USD0.3b, CMP INR502, Buy) Niket Shah (Niket.Shah@MotilalOswal.com) / Atul Mehra (Atul.Mehra@MotilalOswal.com) Revenue declines, margins lower than estimate: PVRL reported sales of INR3.37b (est. INR3.63b), compared to INR2b (ex-Cinemax) in 2QFY13, marking a YoY growth of 69%. Lower revenue in 3QFY14 was primarily as only three big films delivered (Ram Leela, Krrish 3 and Dhoom 3), compared to seven big films (Student of The Year, English Vinglish, Jab Tak Hain Jaan, Son of Sardar, Talaash, Dabangg 2 and Life of Pi) in 3QFY13. EBITDA margin for 3QFY14 stood at 14.6% (est. 17.5%), primarily due to lower operating leverage. Due to lower revenue and margins and tax credit of INR41m, reported PAT stood at INR142m in 3QFY14, against INR91m (ex-Cinemax) in 3QFY13, marking a growth of 55%. Management believes that this quarter was an aberration and expects 25-30% growth in FY15E. Lower growth in Admits, strong growth in SPH and ad revenue: Total footfalls on a consolidated basis stood at 14.3m in 3QFY14, compared to 15.1m, marking a de-growth of 5%, primarily due to 23% decline in footfalls in Cinemax; PVRL showed a growth of 7% YoY. Consolidated ATP stood at INR175, compared to INR168 in 3QFY13, marking a growth of 4%, driven by 4% growth in PVRL and 1% ATP growth in Cinemax. Consolidated SPH stood at INR54 in 3QFY14, compared to INR47 in 3QFY13, marking a growth of 15%, driven by 19% increase in PVRL SPH and 7% growth in Cinemax SPH. Valuation and view: We downgrade the EBITDA for FY14E and FY15E by 8% and 6% respectively. PVRL is a strong long term bet on the multiplex industry, given lower screen density, shift from single screens to multiplex and its leadership position in a movie loving nation. Cinemaxs synergies, structural free cash flows as a result of improvement in mix of newer screens/existing screens will lead to stronger return ratios - RoCE and RoE. The stock is trading at 8.9x and 6.7x FY15E and FY16E EV/EBITDA respectively. We maintain a Buy and value PVRL at 8x FY16E EV/EBITDA and arrive at a target price of INR605.

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.